4-hydroxyphenethyl 3-oxobutanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-hydroxyphenethyl 3-oxobutanoate
• 英文别名: 2-(4-Hydroxyphenyl)ethylacetoacetate；2-(4-hydroxyphenyl)ethyl 3-oxobutanoate
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: ZFKAOTIOKTUFQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-hydroxyphenethyl 3-oxobutanoate 、 β-氨基巴豆酸甲酯 、 间硝基苯甲醛 在 silica gel 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以to yield 5.9 g of 2,6-dimethyl-3-methoxycarbonyl-4-(3-nitrophenyl)-5-[2-(4-hydroxyphenyl)ethoxycarbonyl]-1,4-dihydropyridine (11)的产率得到2,6-dimethyl-3-methoxycarbonyl-4-(3-nitrophenyl)-5-[2-(4-hydroxyphenyl)ethoxycarbonyl]-1,4-dihydropyridine
  参考文献：
  名称：

  Antihypertensive dihydropyridine compositions, optical isomers and

  摘要：

  含有二氢吡啶衍生物的组合物，可用于治疗充血性心力衰竭、高血压或心绞痛，其化学式为：##STR1## 或其药学上可接受的酸加盐，其中n为0至8的整数；Y为--O--、--NH--、--NR.sub.2 --、--S--、--S(O)--、--S(O).sub.2 --或键；R.sub.1和R.sub.2各自独立地为A.sub.1、A.sub.2、A.sub.3或A.sub.4，其中A.sub.1为--(CH.sub.2).sub.m (CHOH).sub.p CH.sub.2 OH；A.sub.2为--(CH.sub.2).sub.q CH.sub.(3-r) [(CH.sub.2).sub.s OH].sub.r；A.sub.3为--(CH.sub.2).sub.q CH.sub.(3-r) [(CH.sub.2).sub.p COOR.sub.3 ].sub.r；A.sub.4为--(CH.sub.2).sub.m COOR.sub.3；其中m为1至8的整数；p为0至4的整数；q为0至8的整数；r为2或3；s为1至4的整数；R.sub.3为H或1至18碳原子的烷基；R.sub.4为--NO.sub.2、--CF.sub.3或卤基；R.sub.5为较低的烷基或--CH.sub.2 CH.sub.2 OCH.sub.3。还公开了上述化合物的光学异构体，以及制备这些最终产物的中间体。

  公开号：

  US04672071A1
• 作为产物：
  描述：

  4-(benzyloxy)phenethyl 3-oxobutanoate 在 钯 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以to afford 4.3 g of 2-(4-hydroxyphenyl)ethylacetoacetate的产率得到4-hydroxyphenethyl 3-oxobutanoate
  参考文献：
  名称：

  Antihypertensive dihydropyridine compositions, optical isomers and

  摘要：

  含有二氢吡啶衍生物的组合物，可用于治疗充血性心力衰竭、高血压或心绞痛，其化学式为：##STR1## 或其药学上可接受的酸加盐，其中n为0至8的整数；Y为--O--、--NH--、--NR.sub.2 --、--S--、--S(O)--、--S(O).sub.2 --或键；R.sub.1和R.sub.2各自独立地为A.sub.1、A.sub.2、A.sub.3或A.sub.4，其中A.sub.1为--(CH.sub.2).sub.m (CHOH).sub.p CH.sub.2 OH；A.sub.2为--(CH.sub.2).sub.q CH.sub.(3-r) [(CH.sub.2).sub.s OH].sub.r；A.sub.3为--(CH.sub.2).sub.q CH.sub.(3-r) [(CH.sub.2).sub.p COOR.sub.3 ].sub.r；A.sub.4为--(CH.sub.2).sub.m COOR.sub.3；其中m为1至8的整数；p为0至4的整数；q为0至8的整数；r为2或3；s为1至4的整数；R.sub.3为H或1至18碳原子的烷基；R.sub.4为--NO.sub.2、--CF.sub.3或卤基；R.sub.5为较低的烷基或--CH.sub.2 CH.sub.2 OCH.sub.3。还公开了上述化合物的光学异构体，以及制备这些最终产物的中间体。

  公开号：

  US04672071A1

文献信息

• Isolation of polyphenol compounds from olive waste and inhibition of their derivatives for <i>α</i>-glucosidase and <i>α</i>-amylase
  作者：Zhihong Wang、Sheng Peng、Mijun Peng、Chengzhang Wang

  DOI：10.1080/14786419.2018.1538217

  日期：2020.8.17

  Olive waste was used as a sustainable resource because it contained a variety of valuable compounds. The polyphenols active fraction from enrichment by microporous resin and extraction with ethyl acetate were analysed by different chromatographic methods. A total of 14 polyphenolic compounds were isolated and identified by structure elucidation. Based on the above obtained compounds, tyrosol was selected as a characteristic polyphenol and participated in transesterification reaction to synthesise beta-ketoester using Yb(OTf)(3). Then the Biginelli reaction with benzaldehyde, urea and ketoester (1:1.2:1.2) was performed at 90 degrees C for 3.0 h under the acidic condition. In addition, the beta-ketoester prepared using tyrosol with benzyl had a greater inhibitory effect on alpha-glucosidase and alpha-amylase, and the inhibition of enzyme activity for 3, 4-dihydropyrimidinone derivatives prepared using abovementioned beta-ketoester was improved significantly. Meanwhile, fluorine-containing dihydropyrimidinone derivatives were considerable inhibitors for both enzymes.
• Antihypertensive dihydropyridine compositions, optical isomers and
  申请人：Syntex (U.S.A.) Inc.

  公开号：US04672071A1

  公开（公告）日：1987-06-09

  Compositions containing dihydropyridine derivatives which are useful for treating congestive heart failure, hypertension, or angina have the formula: ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n is an integer from 0 to 8; Y is --O--, --NH--, --NR.sub.2 --, --S--, --S(O)--, --S(O).sub.2 --, or a bond; R.sub.1 and R.sub.2 are each independently A.sub.1, A.sub.2, A.sub.3 or A.sub.4 where A.sub.1 is --(CH.sub.2).sub.m (CHOH).sub.p CH.sub.2 OH; A.sub.2 is --(CH.sub.2).sub.q CH.sub.(3-r) [(CH.sub.2).sub.s OH].sub.r ; A.sub.3 is --(CH.sub.2).sub.q CH.sub.(3-r) [(CH.sub.2).sub.p COOR.sub.3 ].sub.r ; and A.sub.4 is --(CH.sub.2).sub.m COOR.sub.3 ; where m is an integer from 1 to 8; p is an integer from 0 to 4; q is an integer from 0 to 8; r is 2 or 3; s is an integer from 1 to 4; and R.sub.3 is H or alkyl of 1 to 18 carbon atoms; R.sub.4 is --NO.sub.2, --CF.sub.3, or halo; and R.sub.5 is lower alkyl or --CH.sub.2 CH.sub.2 OCH.sub.3. Also disclosed are optical isomers of the above compounds, as well as intermediates in the preparation of these final products.

  含有二氢吡啶衍生物的组合物，可用于治疗充血性心力衰竭、高血压或心绞痛，其化学式为：##STR1## 或其药学上可接受的酸加盐，其中n为0至8的整数；Y为--O--、--NH--、--NR.sub.2 --、--S--、--S(O)--、--S(O).sub.2 --或键；R.sub.1和R.sub.2各自独立地为A.sub.1、A.sub.2、A.sub.3或A.sub.4，其中A.sub.1为--(CH.sub.2).sub.m (CHOH).sub.p CH.sub.2 OH；A.sub.2为--(CH.sub.2).sub.q CH.sub.(3-r) [(CH.sub.2).sub.s OH].sub.r；A.sub.3为--(CH.sub.2).sub.q CH.sub.(3-r) [(CH.sub.2).sub.p COOR.sub.3 ].sub.r；A.sub.4为--(CH.sub.2).sub.m COOR.sub.3；其中m为1至8的整数；p为0至4的整数；q为0至8的整数；r为2或3；s为1至4的整数；R.sub.3为H或1至18碳原子的烷基；R.sub.4为--NO.sub.2、--CF.sub.3或卤基；R.sub.5为较低的烷基或--CH.sub.2 CH.sub.2 OCH.sub.3。还公开了上述化合物的光学异构体，以及制备这些最终产物的中间体。